Industry Revenues:

• Healthcare: 100% (2025)

TOP 3 Markets:

• USA: 60%
• Europe: 25%
• Australia: 15%

Pro Medicus Limited generates all its revenues from the healthcare industry, particularly through the provision of software solutions for medical imaging. The USA is the company's largest market, followed by Europe and Australia. Together, these markets account for the majority of the revenue, with the US market contributing more than half of the sales.

Production Sites: Australia, USA, Germany

Pro Medicus Limited, a leading company in the field of medical imaging and IT solutions, mainly produces its products in Australia, where the company is headquartered. In addition, Pro Medicus also has significant branches in the USA and Germany, which contribute to the development and customization of their software solutions.

These international sites enable the company to adapt its products to the specific requirements of each market while also benefiting from technological advancements in these regions.

Growth Strategy:

1. International Expansion: Continuing expansion in the USA and Europe.
2. Product Innovation: Developing new features and expanding existing software solutions.
3. Partnerships: Expanding strategic alliances with leading healthcare providers.

Pro Medicus Limited pursues a growth strategy that heavily focuses on international expansion, particularly in the USA and Europe, where the demand for advanced medical imaging solutions is growing. The company continuously invests in research and development to innovate its products and integrate new features that meet the needs of modern healthcare.

In addition, Pro Medicus relies on strategic partnerships with major healthcare providers to strengthen its market presence and gain access to new customer segments. This strategy aims to further enhance its market leadership in medical imaging technology and ensure long-term growth.

Commodities/Materials: Software components and IT hardware
Main importing countries: USA, Germany, China

Pro Medicus Limited is a company specializing in medical imaging solutions. As the company mainly offers software solutions, the essential "commodities" consist of software components and IT hardware needed for the operation and development of their products.

The USA and Germany are leaders in software development and IT technology, which is why Pro Medicus likely imports software components and specialized IT hardware from these countries. China is a significant manufacturer of IT hardware, making it another important importing country for Pro Medicus.

Since Pro Medicus is a technology-oriented company, physical commodities are less relevant than the software and IT infrastructure they utilize.

Market Share: 25% in the field of medical imaging (2025, estimated)
R&D Expenses: 12% of revenue (2024)
Customer Satisfaction: 4.8 out of 5 (2024, based on surveys)

Pro Medicus Limited has established itself as a leading provider in the field of medical imaging, particularly through its highly advanced software solutions. The company's competitive advantage lies in its advanced technology, which enables faster and more accurate diagnosis.

Another key factor is the high proportion of research and development, which allows the company to continuously develop and bring innovative products to the market. This not only strengthens its market position but also increases customer satisfaction, as reflected in the high ratings.

In addition, Pro Medicus benefits from long-term contracts with large hospitals and health networks, ensuring stable revenue and a strong market presence. The company's competitive advantage is further solidified by its ability to quickly adapt to technological changes and seize new market opportunities.

Institutional Investor Share: approximately 60% (estimated, 2025)
Insider Buys/Sells: No significant transactions in the last quarter (estimated, 2025)

The institutional investor share in Pro Medicus Limited is estimated to be around 60%. This demonstrates the confidence of large investors in the company's long-term growth strategy.

Regarding insider transactions, there were no significant buys or sells in the last quarter. This could indicate that the management is satisfied with the current company performance and sees no need to alter their holdings.

Market share of Pro Medicus Limited: Estimate 5% (2025)

Top competitors and market shares:

1. Philips Healthcare: Estimate 20%
2. GE Healthcare: Estimate 18%
3. Siemens Healthineers: Estimate 15%
4. Agfa HealthCare: Estimate 10%
5. Fujifilm Medical Systems: Estimate 8%
6. Carestream Health: Estimate 7%
7. Pro Medicus Limited: Estimate 5%
8. Sectra AB: Estimate 4%
9. Intelerad Medical Systems: Estimate 3%
10. Merge Healthcare (IBM): Estimate 2%

Moat of Pro Medicus Limited:

Pro Medicus Limited has made a name for itself through specialized software solutions in the field of medical imaging and IT services. Their main advantage lies in technological innovation and the high quality of their products, which are appreciated by many large hospitals and medical facilities worldwide.

Compared to larger competitors like Philips Healthcare and GE Healthcare, which have extensive product portfolios and global distribution networks, the moat of Pro Medicus is more focused on niche markets and specialized applications. This allows them to be leaders in certain segments, even though they have a smaller overall market share.

Larger companies often benefit from economies of scale and a broader product range, giving them a stronger moat in terms of market presence and customer loyalty. Nevertheless, Pro Medicus remains competitive through continuous innovation and excellent customer service.

Revenue Growth: 18% (2024) Profit Growth: 20% (2024) R&D Investments: 12% of revenue (2024)

Pro Medicus Limited achieved strong revenue growth of 18% in 2024, attributed to successful implementation of new technologies and expansion into international markets. The company also reached a profit growth of 20%, indicating efficient cost controls and high demand for their medical imaging solutions.

Another positive aspect is the investment in research and development, accounting for 12% of revenue. This demonstrates the company's commitment to continuously enhance its technological capabilities and develop innovative products that meet market requirements.

The strong financial performance and strategic investments in R&D suggest that Pro Medicus is well positioned to achieve further growth in the future. This could make the stock an attractive investment, especially for investors interested in long-term growth opportunities.

Dividend yield: 1.2% (2025)
Dividend growth: 10% annually (last 3 years)

Pro Medicus Limited pays a dividend that currently offers a yield of about 1.2%. Over the past three years, the company has increased its dividend by an average of 10% per year, indicating a positive trend and a solid financial foundation.

The reliability of Pro Medicus' dividend payments is high, as the company has regularly paid dividends in the past. The strong market position in the field of medical imaging and continuous revenue growth support the company's ability to continue paying dividends in the future.